Details

Autor(en) / Beteiligte

• Qi PEI Qiong HUANG Guo-ping YANGI Ying-chun ZHAO Ji-ye YIN Min SONG Yi ZHENG Zhao-hui MO Hong-hao ZHOU Zhao-qian LIU

Titel

PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients＇ response to pioglitazone in China

Ist Teil von

• 中国药理学报：英文版, 2013 (2), p.255-261

Erscheinungsjahr

2013

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Aim： To investigate the influence of peroxisome proliferator-activated receptor y2 （PPAR-y2） gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D （PTPRD） gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods： One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone （30 mg/d, po） for 3 months. All the subjects were genotyped for genetic variants in PPAR-~2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results： The PPAR-y2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility （0R=0.515, 95% Cl 0.268-0.990） and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes （0R=1.984, 95% Cl 1.135-3.469） in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-y2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT＋TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion： Diabetes risk alleles in PPAR-y2 （rs1801282） and PTPRD （rs17584499） are associated with pioglitazone therapeutic efficacy.